{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T05:57:13Z","timestamp":1759730233782,"version":"3.44.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ygyno.2020.05.014","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T07:36:39Z","timestamp":1591169799000},"page":"440-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing"],"prefix":"10.1016","volume":"158","author":[{"given":"Susan Randall","family":"Armel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Volenik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rochelle","family":"Demsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Malcolmson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjula","family":"Maganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanna","family":"McCuaig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Canadian Cancer Statistics 2019","author":"Canadian Cancer Statistics Advisory Committee","key":"10.1016\/j.ygyno.2020.05.014_bb0005"},{"year":"2019","series-title":"Cancer Facts & Figures 2019","author":"American Cancer Society","key":"10.1016\/j.ygyno.2020.05.014_bb0010"},{"key":"10.1016\/j.ygyno.2020.05.014_bb0015","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0020","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2010.05.011","article-title":"Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube","volume":"118","author":"Vicus","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186043","article-title":"Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1)","volume":"12","author":"Harter","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.05.014_bb0040","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2013.05.003","article-title":"Keeping it simple: genetics referrals for all invasive serous ovarian cancers","volume":"130","author":"Demsky","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0050","doi-asserted-by":"crossref","first-page":"29506","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ygyno.2017.06.002","article-title":"Multi-disciplinary summit on genetics services for women with gynecologic cancers: a Society of Gynecologic Oncology White Paper","volume":"146","author":"Randall","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet. Med."},{"year":"2019","series-title":"Genetic\/Familial High-risk Assessment: Breast, Ovarian, and Pancreatic","author":"NCCN","key":"10.1016\/j.ygyno.2020.05.014_bb0065"},{"key":"10.1016\/j.ygyno.2020.05.014_bb0070","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1097\/AOG.0000000000002296","article-title":"Practice bulletin no 182: hereditary breast and ovarian cancer syndrome","volume":"130","author":"Committee on Practice Bulletins\u2013Gynecology Committee on Genetics Society of Gynecologic Oncology","year":"2017","journal-title":"Obstet. Gynecol."},{"issue":"11","key":"10.1016\/j.ygyno.2020.05.014_bb0075","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0080","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","article-title":"National estimates of genetic testing in women with a history of breast or ovarian cancer","volume":"35","author":"Childers","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/IGC.0000000000000907","article-title":"Genetics consultation rates following a diagnosis of high-grade serous ovarian carcinoma in the Canadian Province of Ontario","volume":"27","author":"McGee","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.05.014_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2015.04.029","article-title":"Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals","volume":"138","author":"Febbraro","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0095","first-page":"493","article-title":"Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: a review of the literature","volume":"67","author":"Hoskins","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0100","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/IGC.0b013e3182994365","article-title":"Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"23","author":"Novetsky","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.05.014_bb0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10897-017-0135-2","article-title":"Cancer genetic counseling and testing: perspectives of epithelial ovarian cancer patients and gynecologic oncology healthcare providers","volume":"27","author":"Liang","year":"2018","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ygyno.2011.09.040","article-title":"There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer","volume":"124","author":"Meiser","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0115","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/jmedgenet-2018-105472","article-title":"Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap","volume":"55","author":"McCuaig","year":"2018","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0120","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12885-018-4153-8","article-title":"A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention","volume":"18","author":"Hanley","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.05.014_bb0125","doi-asserted-by":"crossref","first-page":"6029097","DOI":"10.1155\/2019\/6029097","article-title":"Direct genetics referral pathway for high-grade serous ovarian cancer patients: the \u201copt-out\u201d process","volume":"2019","author":"McGee","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0130","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/IGC.0000000000000689","article-title":"Impact of clinical genetics attendance at a gynecologic oncology tumor board on referrals for genetic counseling and BRCA mutation testing","volume":"26","author":"Cohen","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.05.014_bb0135","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2017.01.030","article-title":"Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics","volume":"145","author":"Kentwell","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0140","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2017.07.141","article-title":"Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care","volume":"147","author":"Senter","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0145","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10897-012-9505-y","article-title":"Report from the National Society of Genetic Counselors service delivery model task force: a proposal to define models, components, and modes of referral","volume":"21","author":"Cohen","year":"2012","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0150","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1200\/JCO.2017.76.2781","article-title":"Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer","volume":"36","author":"Colombo","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0155","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s10897-014-9813-5","article-title":"All in the family: barriers and motivators to the use of cancer family history questionnaires and the impact on attendance rates","volume":"24","author":"Armel","year":"2015","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0160","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cge.13654","article-title":"Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center","volume":"97","author":"Mallen","year":"2020","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0165","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/ajo.12964","article-title":"Referral patterns for genetic counselling of women diagnosed with tubo- ovarian or peritoneal high- grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre","volume":"59","author":"Burling","year":"2019","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.05.014_bb0170","article-title":"Genetic counselling referral rates and uptake of BRCA1 and BRCA2 testing among women diagnosed with serous ovarian cancer in a tertiary care cancer centre","volume":"4","author":"Bell","year":"2013","journal-title":"J. Genet. Syndr. Gene Ther."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000431352","article-title":"Referral of ovarian cancer patients for genetic counselling by oncologists: need for improvement","volume":"18","author":"Ricci","year":"2015","journal-title":"Publ. Health Genom."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0180","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s10897-013-9598-y","article-title":"Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic","volume":"22","author":"Petzel","year":"2013","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0185","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2015.03.057","article-title":"The sooner the better: genetic testing following ovarian cancer diagnosis","volume":"137","author":"Fox","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0190","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ygyno.2017.05.037","article-title":"A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment","volume":"146","author":"Bednar","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0195","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.05.014_bb0200","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820310829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820310829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:52:35Z","timestamp":1758772355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820310829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0090825820310829"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}